Portal vein thrombosis, mortality and hepatic decompensation in patients with cirrhosis: A meta-analysis

Table 2 Patient level characteristics n (%)

	Englesbe 20101		John 20132		Maruyama 20133
	No PVT (n = 3147)	PVT (n = 148)	No PVT (n = 220)	PVT (n = 70)	No PVT (n = 108)	PVT (n = 42)
Sex (M/F)	1905/1242	91/57	144/76	42/28	63/45	22/20
Race
Black	218 (6.9)	7 (4.7)	-	-	-	-
White	-	-	184 (83.6)	60 (85.7)	-	-
Other	2545 (80.9)	131 (88.5)			-	-
	"Nonblack"	"Nonblack"	-	-
Etiology
AIH	95 (3)	8 (5.4)	-	-	-	-
Biliary/cholestatic	173 (5.4)	7 (5.4)	24 (11)	5 (7.1)	-	-
Alcohol	672 (21.4)	31 (20.9)	37 (16.9)	5 (7.1)	-	-
Viral	1253 (39.8)	50 (34.1)	62 (28.3)	16 (27.1)	108	42
Cryptogenic/NASH	72 (2.3)	0	35 (16)	12 (17.1)	-	-
Other	449 (14.3)	22 (14.9)	37 (16.9)	20 (28.6)	-	-
Age (yr)	51.5 ± 11.2	50.9 ± 10.8	55.8 ± 9.1	58.4 ± 8.8	63.3 ± 8.68	62.4 ± 11
MELD	12.1 ± 7.2	13.3 ± 8.3	13.8 ± 4.5	14.9 ± 5.9	10.2	10.6

¹Presence of PVT at time of initial transplant evaluation or during the pre-transplant period;

²PVT category includes patients with PVT at baseline (n = 47) and those that developed new PVT during the study period (n = 23);

³Study only assessed patients with viral hepatitis. No data reported for race. PVT: Portal vein thrombosis; MELD: Model for end stage liver disease; NASH: Non-alcoholic steatohepatitis; M/F: Male/female; AIH: Autoimmune hepatitis.